Stuart Isaacson

Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial

Jeffrey L. Cummings, Stuart Isaacson, Roger Mills et al. · The Lancet · 2013 · 926 citations

Disease Psychosis, Psychoactive Drug, Placebo-controlled Phase 3 +13

Safety and Tolerability of Multiple Ascending Doses of PRX002/RG7935, an Anti–α-Synuclein Monoclonal Antibody, in Patients With Parkinson Disease

Joseph Jankovic, Ira Goodman, Beth Safirstein et al. · JAMA Neurology · 2018 · 283 citations · Full text

Inosine to Increase Serum and Cerebrospinal Fluid Urate in Parkinson Disease

Michael A. Schwarzschild, Alberto Ascherio, M. Flint Beal et al. · JAMA Neurology · 2014 · 234 citations · Full text

ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson Disease (EASE LID Study)

Rajesh Pahwa, Caroline M. Tanner, Robert A. Hauser et al. · JAMA Neurology · 2017 · 170 citations · Full text

Randomized, placebo‐controlled trial of ADS‐5102 (amantadine) extended‐release capsules for levodopa‐induced dyskinesia in Parkinson's disease (EASE LID 3)

Wolfgang H. Oertel, Karla Eggert, Rajesh Pahwa et al. · Movement Disorders · 2017 · 163 citations · Full text